Evrópusambandið - íslenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - Æxlishemjandi lyf - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation (i)* - trimethoprimum inn - filmuhúðuð tafla - 160 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - ceftriaxonum dínatríum - stungulyfs-/innrennslisstofn, lausn - 1 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

eql pharma ab - doxycyclinum inn - tafla - 100 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - rabeprazolum natríum - magasýruþolin tafla - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

amdipharm limited* - acidum fusidicum inn - augndropar, dreifa - 10 mg/g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - omeprazolum inn - magasýruþolið hart hylki - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - omeprazolum inn - magasýruþolið hart hylki - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - omeprazolum inn - magasýruþolið hart hylki - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ceftazidimum inn - stungulyfs-/innrennslisstofn, lausn - 2 g